Anemia in Elderly Market Report 2026

The anemia in elderly market size has grown strongly in recent years. It will grow from $2.99 billion in 2025 to $3.26 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to aging population growth, increased prevalence of chronic diseases, availability of oral iron supplements, expansion of hospital-based anemia management, rising awareness of nutritional deficiencies.

The anemia in elderly market size is expected to see strong growth in the next few years. It will grow to $4.59 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growing demand for personalized anemia treatment, increasing adoption of long-acting injectables, rising focus on geriatric healthcare, expansion of outpatient anemia management, improved diagnostic screening in elderly care. Major trends in the forecast period include increasing adoption of combination therapy approaches, rising use of injectable iron treatments, growing focus on early diagnosis in elderly populations, expansion of home-based treatment options, enhanced emphasis on managing chronic disease-related anemia.

The expanding elderly population is anticipated to drive the growth of the anemia in the elderly market in the coming years. The elderly population refers to the rising number and proportion of individuals aged 65 years and above within a society or across the globe. This growth is driven by factors such as longer life expectancy, declining birth rates, and the aging of large population cohorts. An increase in the elderly population leads to a higher prevalence of age-related and chronic diseases, which are major contributors to anemia among older adults. As a result, the demand for anemia diagnosis, management, and treatment increases, supporting market expansion. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, reported that the population of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, this age group’s share of the total population is expected to grow from 17% to 23% over the same period. Consequently, the growing elderly population is contributing significantly to the expansion of the anemia in the elderly market.

Major companies operating in the anemia in the elderly market are emphasizing technological advancements, including personalized therapies, to simplify treatment processes, enhance patient outcomes, minimize side effects, and improve overall healthcare efficiency. Personalized therapies are medical treatments tailored to the unique characteristics of individual patients. For example, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, announced the launch of Redshot FCM, an innovative iron injection developed to treat iron deficiency anemia in patients who are intolerant to oral iron. This intravenous iron formulation delivers sufficient iron levels while maintaining a strong safety profile. It incorporates an advanced Ferric Carboxymaltose formulation that enhances iron delivery and absorption. Redshot FCM reflects a commitment to advancing healthcare through the development of personalized therapies that consider individual patient needs, ultimately leading to improved treatment outcomes for iron deficiency anemia.

In February 2025, AstraZeneca, a UK-based biopharmaceutical company, acquired FibroGen, Inc. for $160 million. Through this acquisition, AstraZeneca seeks to enhance its footprint in the Chinese anemia therapeutics market by obtaining full rights to roxadustat, including its manufacturing, development, and commercialization activities. FibroGen, Inc. is a US-based biopharmaceutical company engaged in the development of innovative therapies at the forefront of cancer biology and anemia.

Major companies operating in the anemia in elderly market are Johnson & Johnson, Roche Holding AG, Merck & Co Inc, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Japan Tobacco Inc, Fresenius Medical Care AG, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, CSL Limted, Daiichi Sankyo Company Limited, Amag Pharmaceuticals, Akebia Therapeutics Inc, Pharmacosmos A/S, Rockwell Medical Inc, Bioage Labs Inc, Shield Therapeutics Plc, MegaPro Biomedical Co Ltd.

North America was the largest region in the anemia in elderly market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia in elderly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anemia in elderly market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the anemia in elderly market by increasing costs of imported pharmaceutical ingredients, injectable formulations, medical packaging materials, and specialized manufacturing equipment. Healthcare systems in North America and Europe are most affected due to dependence on global drug supply chains, while Asia-Pacific faces cost pressures on generic drug production inputs. These tariffs are contributing to higher therapy costs and supply fluctuations. However, they are also encouraging domestic pharmaceutical manufacturing, regional sourcing of raw materials, and greater investment in local production of anemia therapeutics.

The anemia in elderly market research report is one of a series of new reports that provides anemia in elderly market statistics, including anemia in elderly industry global market size, regional shares, competitors with a anemia in elderly market share, detailed anemia in elderly market segments, market trends and opportunities, and any further data you may need to thrive in the anemia in elderly industry. This anemia in elderly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anemia in older adults is a condition marked by a decrease in red blood cell (RBC) count or hemoglobin levels below normal values, resulting in reduced oxygen transport in the blood among elderly individuals (typically those aged 65 years and above). It commonly arises due to nutritional deficiencies, chronic medical conditions, or physiological changes associated with aging.

The primary product types used to treat anemia in the elderly include tablets and injectables. Tablets are solid oral medications that are widely prescribed for managing anemia in older adults. The various treatment options include iron supplements, erythropoietin or erythrocyte-stimulating agents, vitamin B12 supplements, and folic acid supplements. The routes of administration vary between oral and parenteral, and these products are distributed through end users such as hospital pharmacies, online pharmacies, and retail pharmacies.

The anemia in elderly market consists of revenues earned by entities by providing services such as diagnostic testing, medical consultations and treatment plans, and administration of iron infusions or blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The anemia in elderly market also includes sales of iron supplements, vitamin B12, folic acid supplements, and diagnostic equipment such as hemoglobin meters and blood test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.